{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-111207","form_type":"8-K","ticker":"INMB","cik":"0001711754","company_name":"Inmune Bio, Inc.","filed_at":"2026-10-21T13:00:34+00:00","discovered_at":"2026-10-21T13:02:00.092502+00:00","generated_at":"2026-10-21T13:02:09.695032+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"INmune Bio submits Ebstrocel pre-MAA to UK MHRA, targets approval in mid-2027","bullets":["Submitted final pre-MAA package for Ebstrocel (CORDStrom) to the UK MHRA on October 20, 2026; full MAA targeted for early February 2027.","INmune Bio says the revised strategy could accelerate potential UK approval by about six weeks, with possible approval in mid-2027 subject to MHRA review.","Signed a Master Services Agreement with Uniphar Durbin Ireland to support named-patient access in selected European and MENA markets.","Plans a Type B meeting request with the FDA and a BLA submission in Q2 2027, seeking traditional or accelerated approval as appropriate."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-111207","json":"https://secwatch.observer/filing/0001213900-26-111207.json","markdown":"https://secwatch.observer/filing/0001213900-26-111207.md","text":"https://secwatch.observer/filing/0001213900-26-111207.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711754/000121390026111207/0001213900-26-111207-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711754/000121390026111207/ea0309223-8k_inmune.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-21T13:02:09.695032+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}